Corporate Presentation

June 2017

Disclaimer

The statements made in this presentation may include forward-looking statements regarding

the future operations of ERYTECH Pharma S.A., including estimates of target market

opportunity, timing of planned clinical trials and results from those trials, regulatory strategy

and timing of planned regulatory submissions, manufacturing capabilities and strategy for

expansion of the ERYCAPS platform. Although we believe that the expectations contained in

this presentation are reasonable, these forward-looking statements are only estimations

based upon the information available to ERYTECH Pharma S.A. as of the date of this

presentation. Except as required by law, we expressly disclaim any responsibility to publicly

update or revise our forward-looking statements, whether as a result of new information,

future events or otherwise. Thus, the forward-looking statements herein involve known and

unknown risks and uncertainties and other important factors such that actual future

operations, opportunities or financial performance may differ materially from these forward-

looking statements. Undue reliance should not be placed on forward looking statements,

which speak only as of the date hereof. All forward-looking statements contained herein are

qualified in their entirety by the foregoing cautionary statement.

2

ERYTECH, leveraging red blood cells to improve cancer treatment

Innovative and versatile ERYCAPS technology platform, encapsulating drugs in red blood cells

1

Targeting indications with high unmet medicalneed

2

Lead product eryaspase (GRASPA) in late-stage development in leukemia and pancreatic cancer3

Attractive long term growth opportunities andstrategic optionality

5

Significant opportunity in pancreatic cancerfollowing positive Phase 2b

4

3

ERYCAPS, an innovative and versatile technology platform

Entrapment of drug substance inside donor-derived red blood cellsusing hypotonic/hypertonic stress

Resealing

(hypertonic stress)

Controlled lysis

(hypotonic stress)

Proprietary ‘osmoticfragility’ process ensuresrequired amount of drugin each RBC batch

Molecules from 1 to 500 kDalton (peptides, enzymes, antigens, ...)

Protected by 13 patent families

Industrialized in commercial scale GMP manufacturing facility

4

ERYCAPS, two main modes of action, broad application potential

Rapid & specific targeting of immune cells in spleen, liver

or bone marrow

Additional treatment of RBC

membrane

Long circulating systemicactivity with reduced toxicity

Examples of applications

Enzymes targeting cancer metabolism(E.g., asparaginase in ALL, AML, PDAC)

Enzymes for enzyme therapies(E.g., methioninase in homocystinuria)

Antigens for cancer immunotherapies(E.g., TRP2 in melanoma)

Antigens for tolerance induction (E.g., tolerance to alglucosidase-α)

5

Broad clinical pipeline building on ERYCAPS platform

Mode of

action

Product

Candidate/

PROGRAM

Drug

substanceIndication Discovery

Pre-

clinicalPhase 1 Phase 2

Phase 3/

Pivotal

EMA/FDA

review

Commercial

Rights

Cancer

metabolism

Tumor

starvation

eryaspase

(GRASPA®(1))Asparaginase

ALLEurope

Israel

AMLUS and RoW

Pancreatic

cancer

Solid

tumors

ery-

methionase

Methionine-

γ-lyase

Solid

tumors

eryminaseArginine

deiminase

Solid

tumors

Enzyme

therapiesERYZYME

Therapeutic

enzymes

Metabolic

diseases

Immuno-

therapyERYMMUNE

Tumor

antigensTBD

EU then EU/US

EU then EU/US

US

EU

(1) Brand name for eryaspase in Europe and Israel6

Asparaginase, cornerstone treatment in ALL therapy

Concept

Target

Therapy

• Starving cancer cells by targeting their amino acid metabolism

• Asparagine, essential nutrient for most tumor cells (1), but not for normal cells

• Asparaginase, degrades asparagine and deprives tumor cells of asparagine

Limitations

• Important side effects (allergies, coagulation disorders, pancreatic and hepatic toxicities) limiting treatment utilityin patients with poor performance status

• Neutralizing antibodies leading to decreased activity

• Proven efficacy; cornerstone in Phi-negpediatric ALL therapy

(1) Asparagine synthetase (ASNS) deficient cells, unable to synthetize asparagine.

7

Eryaspase (GRASPA®), a novel ‘bioreactor’ to degrade asparagine

The circulating asparagine is actively pumped into the RBC…

Y

Asparagine

Asparaginase

Antibodies

Longer activity

Less toxicity

…where the encapsulated asparaginase hydrolyses it to aspartate and ammonia

Prolonged activity and reduced toxicity thanks to encapsulation of the asparaginase inside the RBC

8

eryaspase (GRASPA) 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018

Relapsed & refractory children & adults – EU

1st line adults >55 yr - FR

Patients ‘at risk’ - children & adults - FR

1st line after PEG-ASP –children & adults - Nordics

1st line Adults - USA

Late stage clinical development in ALL

9

Phase 1/2

Phase 2

Phase 2/3

Completed Ongoing

Expanded Access Program

Phase 1<

Highlights of Phase 2/3 clinical results in relapsed & refractory (R/R) ALL in patients without prior allergies; chemo + GRASPA vs chemo + L-asparaginase:- Significantly less allergic reactions (0% vs 46%)**- Superior duration of asparaginase activity above 100 U/l (20 days vs 8 days) **- Improved complete remission rate after induction phase (75% vs 50%; NS)- Nominal overall survival (OS) benefit (HR = 0.73; NS)- Favorable overall safety profile

** p < 0.001

Phase 2

9

Resubmission of EU MAA for GRASPA in R/R ALL targeted in Q3 2017

• European Marketing Authorization Application (MAA) submitted to European Medicines Agency (EMA) in September 2015, based on results from pivotal Phase 2/3 study

• CHMP’s D180 List of Outstanding Issues received in September 2016 highlighting need for additional data on:

- Comparability(1)

- Immunogenicity

- Pharmacodynamic effects

• Decided to withdraw MAA in November 2016 because additional data requested will take more time to provide than allowed in procedure

• Planning to resubmit the MAA with the additional data by end Q3 2017

10

(1) Comparability between eryaspase with native L-asparaginase encapsulated in the RBCs, as used in the ALL studies to date, and eryaspase produced with the newly approved recombinant L-asparaginase

US Phase 1 in first line adult ALL ongoing

• Open label dose escalation study with eryaspase in combination with CALGB 8811 protocol for 1st line treatment of adult ALL patients

• Principal investigator: Prof. Dr. Richard Larson, University of Chicago

• Five active sites across the US

• Treating patients in second treatment cohort; definition of recommended Phase 2 dosing expected mid 2017

• Planning to discuss further development plans with the FDA in H2 2017

11

• Est. 40,000+ new patients per year (US & EU); poor prognosis and low survival

• Clinical evidence of benefit of asparaginase in AML and ad hoc clinical use

• A disease primarily in elderly patients; the use of asparaginases is prohibitive due to toxicity

• Randomized Phase 2b European study ongoing in AML patients over 65 years of age and unfit for intensive chemotherapy, comparing eryaspase (GRASPA) plus low dose Ara-C (LDAC) versus LDAC alone

- N = 123; randomized 2-to-1

- Primary endpoint: Overall Survival (OS)

- Three IDMC safety reviews passed

- Patient enrollment completed in August 2016

- Reporting of results expected by end Q4 2017

- Study financed by Orphan Europe (Recordati)

• Next steps contingent on outcome of ongoing Phase 2b study

Enrollment completed in EU Phase 2b study in first line AML

12

• Targeting asparagine metabolism to ‘starve tumors’ was known beyond leukemia, but toxicity has limited clinical use of asparaginase in solid tumors

• Tumors with low asparagine synthetase (ASNS) expression status are believed to be most sensitivity to asparaginase treatment(1)

• Pancreatic cancer chosen as first solid tumor indication for ERYTECH based on ASNS and high unmet medical need(2)

• Est. 2/3 of patients have tumors with no or low ASNS expression (ASNS 0/1)

• Est. 150,000 new cases are diagnosed in Europe and the US annually

• Fast growing, expected to grow from 4th to 2nd most morbid cancer by 2025 in US

• A Phase 1 study with eryaspase demonstrated a favorable safety(3)

• A randomized Phase 2b study was launched in 2014

Eryaspase, an opportunity to bring asparaginase to solid tumors?

13

(1) Dufour e.a., 2012(2) Rahib & Smith, 2014`(3) Bachet e.a., 2015

Phase 2b study in pancreatic cancer: study design

14

• Metastatic pancreatic adenocarcinoma

• Second line, previously treated with gemcitabine based chemotherapy or FOLFIRINOX

• Performance status 0 and 1 RA

ND

OM

IZE

2:1

gemcitabine or FOLFOX

(N=46)

gemcitabine or FOLFOX

+ eryaspase(N = 95)

Follo

w u

p

6 cycles of 4 weeks

• N=141 (69% ASNS 0/1, 31% ASNS 2/3)

• Study performed with the GERCOR: 16 centers in France

• Co-primary endpoint: – OS and OS in ASNS 0/1 patients

– Positive if HR <0.85 for either PFS or OS, providing none is >1.0

• Key secondary endpoints:– PFS and OS HR in key treatment populations: all patients, ASNS 0/1, ASNS 2/3

– Safety

Primary endpoints met with clear efficacy signal

• Co-primary endpoint met:

• PFS HR in ASNS 0/1 = 0.73

• OS HR in ASNS 0/1 = 0.62

• PFS and OS results are consistent and robust across subgroups

• ASNS appears not to be predictive of treatment benefit, but seems to be prognostic. Patients with high ASNS have a worse prognosis

15

• Significant survival benefit in total population• OS HR = 0.57 (p=0.034)

43% reduction in risk of death

• Similar results on PFS

• Well-balanced baseline characteristics

• The treatment is generally well tolerated

Other cancer metabolism product candidates in development

• erymethionase (ERY-MET), methione-γ-liase in RBCs, start of a Phase 1 clinical trial targeted in 2018

• eryminase, arginine-deiminase in RBCs, launch of Phase 1 to follow about one year after erymethionase

16

ERY-MET efficacy against gastric tumors (NCI-N87)Mean tumor growth with SEM

Days post-tumor implantation

Me

an

tu

mo

r v

olu

me

s (

mm

3)

20 40 60 80 1000

500

1000

1500

2000Vehicle + PN

ERY-MET + PN

ERY-MET adm.(mean dose: 108IU/kg)

daily IG inj. of PN cofactor

❷

erymethionase efficacy against gastric tumors (NCI-N87)

Beyond tumor starvation: immunotherapy with antigen-loaded RBCs

• Promising proof of concept obtained with RBC-based immunotherapy approach

- Generation of antigen-specific cytotoxic CD4+ and CD8+ T-cells by antigen-loaded RBCs, modified for rapid targeting of antigen-presenting cells (APC) in the spleen

- Preclinical proof of concept with TRP2(1) and PSA(2) loaded RBCs

• Further incubating this technology; new proof of concept data expected Q3 2017

(1) Banz et al, J Immunother, 2012.

(2) Cremel, presentation at CITIM 2015

Days post tumor implantation

Tu

mo

r siz

e (

mm

3)

10 12 14 16 18 200

500

1000

1500Treated RBC-TRP2 + adjuvant

Free TRP2 + adjuvant

Control

GENERATION OF ANTIGEN SPECIFICCYTOTOXIC CD4 & CD8 T-CELLS

ERYTHROPHAGOCYTOSISOF ‘SENESCENT’ ANTIGEN-CONTAINING RBCs BY APC

DELAY OF TUMOR GROWTH

Nu

mb

er o

f T

RP

2-sp

ecif

ic

IFN

g-s

ecre

tin

g c

ells

/10

6 c

ells

0

500

1000

1500

2000

Legend

17

Solid cash balance

• Cash balance of €37.7 million at start Q1 2017

• €7.1 million total net cash utilization in Q1 2017

• €70.5 gross proceeds raised from U.S. and European investors in private placement in April 2017 to:

• Finance the preparatory steps for the launch of potential Phase 3 studies, notably for the pancreatic cancer indication

• Assess the clinical development opportunities for eryaspase for the treatment of other solid tumor indications

• Further strengthen the financial position for our continued development

18

Shareholder base

• Shareholder structure after the April 2017 private placement 1):

AURIGA PARTNERS (FR) 9.8%

RECORDATI 3.7%

BAKER BROTHERS 15.4%

JP MORGAN AM 5.6%

FREE FLOAT 65.5%

(1) Based on available information as of June 1st, 201719

Key upcoming milestones

Reporting of full Phase 2b pancreatic cancer data

Meeting with US and EU agencies on pancreatic cancer development plan

Resubmission of EU marketing authorization application in R/R ALL

Meeting with FDA on ALL further development plan

Preclinical proof of concept data with ERYMMUNE and ERYZYME programs

Results from EU Phase 2b AML study

Launch of Phase 3 study in pancreatic cancer

Launch of Phase 3 study in 1st line adult ALL

Launch of erymethionase (ERY-MET) Phase 1 study

20

www.erytech.com

investors@erytech.com

ERYTECH Pharma SA60 Avenue Rockefeller

69008 LyonFrance

ERYTECH Pharma Inc1 Main Street

Cambridge, MA 01242USA